Mesh Bio and PT Pramita today announced a regional partnership to deliver predictive analytics-powered medical check-ups and preventive health services in Indonesia, extending its footprint across more than 30 centres in Indonesia.
The Memorandum of Understanding (MOU) was signed on 15 March 2023 by Dr Andrew Wu, Co-Founder and CEO of Mesh Bio and Dr Nabil Fachliansyah, Vice President of PT Pramita.It was witnessed by Singapore Minister for Trade & Industry Gan Kim Yong and Indonesian Coordinating Minister for Economic Affairs Airlangga Hartarto as part of the Singapore-Indonesia Leaders’ Retreat held in Singapore.
About Mesh Bio
Mesh Bio is a digital health startup focused on addressing the growing global clinical burden of metabolic diseases driven by an aging population, and challenges in care delivery. Mesh Bio develops clinical decision support analytics and automation solutions for management of chronic disease, such as cardiovascular disease and type 2 diabetes. These solutions enable data driven care delivery, improving patient engagement, and health outcomes. Mesh Bio’s DARA® is a Health Intelligence Platform that empowers precision clinical intervention at scale. Predictive analytics on multidimensional health data streams and clinical workflow automation enables health care providers to enhance operational efficiency, personalise care delivery and increase patient engagement.